Concomitant drugs with low risks of drug–drug interactions for use in oncology clinical trials-Reference-Cited by-同舟云学术

Concomitant drugs with low risks of drug–drug interactions for use in oncology clinical trials

Published:2015-05 Issue:2 Volume:94 Page:189-200
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Ranchon Florence,Vial Thierry,Rioufol Catherine,Hénin Emilie,Falandry Claire,Freyer Gilles,Trillet-Lenoir Véronique,Le Tourneau Christophe,You Benoit^ORCID

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference86 articles.

1. The impact of concomitant medication use on patient eligibility for phase I cancer clinical trials;Borad;J Cancer,2012

2. Clinical–pharmacological strategies to assess drug interaction potential during drug development;Kuhlmann;Drug Saf,2001

3. Drug interactions in cancer therapy;Scripture;Nat Rev Cancer,2006

4. Potential interactions with anticancer agents: a cross-sectional study;Mouzon;Chemotherapy,2013

5. Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms;Ingelman-Sundberg;Naunyn Schmiedebergs Arch Pharmacol,2004

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibitory effect of quercetin-3-O-α-rhamnoside, p-coumaric acid, phloridzin and 4-O-β-glucopyranosyl-cis-coumaric acid on rats liver microsomes cytochrome P450 enzyme activities;Food and Chemical Toxicology;2023-02

2. Studying the right transporter at the right time: an in vitro strategy for assessing drug-drug interaction risk during drug discovery and development;Expert Opinion on Drug Metabolism & Toxicology;2022-10-03

3. Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions;Nature Reviews Endocrinology;2022-05-18

4. Intérêt des activités de pharmacie clinique au sein d’un centre d’essais cliniques de phase précoce en cancérologie et satisfaction des participants;Le Pharmacien Hospitalier et Clinicien;2021-09

5. Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines);Cancer Treatment Reviews;2020-08